What is the most recent earnings date for ADAP stock?
ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) last reported earnings on 8/13/2025.
ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Earnings History & Surprises
NASDAQ:ADAP • US00653A1079
Current stock price
0.0549 USD
-0.01 (-15.15%)
At close:
0.0579 USD
+0 (+5.46%)
After Hours:
ADAP Earnings overview
Past quarterly earnings results for ADAPTIMMUNE THERAPEUTICS-ADR (ADAP), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Nov 11, 2025
- Period
- Q3 / 2025
- EPS Estimate
- -$0.12
- Revenue Estimate
- 3.06M
Last Reported
Most Recent- Release Date
- Aug 13, 2025
- Period
- Q2 / 2025
- EPS Reported
- -$0.02
- EPS Surprise
- 80.59%
- Revenue Surprise
- 33.64%
Beat Rate
Last 8 Quarters 44%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2025 | -0.02 | -0.10 | 80.59% | -108.33% | 13.677M | 10.234M | 33.64% | -89.33% |
| Q1 2025 | -0.19 | -0.15 | -24.87% | -5.56% | 7.285M | 6.298M | 15.67% | 28.30% |
| Q4 2024 | -0.24 | -0.14 | -75.07% | - | 3.222M | 5.59M | -42.36% | 1,294.81% |
| Q3 2024 | -0.01 | -0.13 | 92.37% | 95.00% | 40.901M | 11.396M | 258.91% | 458.83% |
| Q2 2024 | 0.24 | -0.07 | 428.30% | 204.35% | 128.231M | 46.224M | 177.41% | 2,399.63% |
| Q1 2024 | -0.18 | -0.10 | -80.07% | -3,100.00% | 5.678M | 9.367M | -39.38% | -88.07% |
| Q4 2023 | -0.24 | -0.10 | -135.29% | -33.33% | 231K | 20.876M | -98.89% | -97.91% |
| Q3 2023 | -0.20 | -0.14 | -42.60% | 16.67% | 7.319M | 10.489M | -30.22% | 4.41% |
| Q2 2023 | -0.23 | -0.14 | -69.36% | 17.86% | 5.13M | 8.957M | -42.73% | -7.40% |
| Q1 2023 | 0.01 | -0.15 | 104.05% | 102.00% | 47.601M | 5.027M | 846.91% | 1,229.64% |
| Q4 2022 | -0.18 | -0.25 | 28.94% | 25.00% | 11.03M | 4.208M | 162.12% | 676.76% |
| Q3 2022 | -0.24 | -0.25 | 2.64% | 20.00% | 7.01M | 4.118M | 70.23% | 484.17% |
| Q2 2022 | -0.28 | -0.25 | -11.97% | -16.67% | 5.54M | 6.286M | -11.87% | 78.71% |
| Q1 2022 | -0.30 | -0.22 | -34.10% | -25.00% | 3.58M | 3.351M | 6.83% | 732.56% |
| Q4 2021 | -0.24 | 0.14 | -268.07% | - | 1.42M | 98.379M | -98.56% | -5.33% |
| Q3 2021 | -0.30 | -0.27 | -10.99% | -25.00% | 1.2M | 1.399M | -14.22% | 0.84% |
| Q2 2021 | -0.24 | -0.25 | 3.88% | - | 3.1M | 1.384M | 123.99% | 520.00% |
| Q1 2021 | -0.24 | -0.26 | 5.88% | - | 430K | 1.87M | -77.01% | -43.42% |
| Q4 2020 | -0.24 | -0.24 | -1.28% | - | 1.5M | 2.023M | -25.85% | - |
| Q3 2020 | -0.24 | -0.26 | 7.36% | - | 1.19M | 888.859K | 33.88% | - |
| Q2 2020 | -0.24 | -0.24 | 0.02% | - | 500K | 951.997K | -47.48% | - |
| Q1 2020 | -0.24 | -0.26 | 7.12% | - | 760K | 23.751M | -96.80% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
18.25%
Max EPS beat (4)
92.37%
Min EPS beat (4)
-75.07%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
66.46%
Max Revenue beat (4)
258.91%
Min Revenue beat (4)
-42.36%
Analysis
In the last 4 quarters, ADAP has beaten EPS estimates in 2 out of 4 releases
ADAP has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, ADAP has beaten the EPS estimates by 18.3% on average.
In the last 4 quarters, ADAP has beaten the revenue estimates by 66.5% on average.
Related analysis
ADAPTIMMUNE THERAPEUTICS-ADR / ADAP Earnings FAQ
Did ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) beat earnings estimates last quarter?
ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) beat EPS estimates and beat revenue estimates in the most recent quarter.
How often does ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) beat earnings estimates?
In the last 4 quarters, ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) has beaten EPS estimates in 2 out of 4 releases.